You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameChlorothiazide
Accession NumberDB00880  (APRD00721)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812)
Structure
Thumb
Synonyms
6-Chloro-1,1-dioxo-1,2-dihydro-1lambda*6*-benzo[1,2,4]thiadiazine-7-sulfonic acid amide
6-chloro-7-Sulfamoyl-2H-1,2,4-benzothiadiazine 1,1-dioxide
Chlorothiazid
Chlorothiazide
Chlorothiazidum
Chlorthiazide
Clorotiazida
Mechlozid
Uroflux
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Chlorothiazide SodiumInjection500 mg/1IntravenousAkorn, Inc.2012-08-13Not applicableUs
DiurilSuspension250 mg/5mLOralSalix Pharmaceuticals, Inc1962-02-15Not applicableUs
Sodium DiurilInjection.5 mg/18mLIntravenousOak Pharmaceuticals, Inc. (Subsidiary of Akorn, Inc.)1958-10-03Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ChlorothiazideTablet500 mg/1OralGolden State Medical Supply, Inc.2005-08-30Not applicableUs
ChlorothiazideTablet250 mg/1OralWest ward Pharmaceutical Corp2005-08-30Not applicableUs
ChlorothiazideInjection, powder, lyophilized, for solution500 mg/18mLIntravenousFresenius Kabi USA, LLC2009-10-21Not applicableUs
ChlorothiazideTablet500 mg/1OralWest ward Pharmaceutical Corp2005-08-30Not applicableUs
ChlorothiazideTablet250 mg/1OralMylan Pharmaceuticals Inc.1975-06-26Not applicableUs
ChlorothiazideTablet250 mg/1OralGolden State Medical Supply, Inc.2005-08-30Not applicableUs
ChlorothiazideTablet250 mg/1OralAvera Mc Kennan Hospital2015-03-01Not applicableUs
ChlorothiazideTablet500 mg/1OralMylan Pharmaceuticals Inc.1975-07-17Not applicableUs
Chlorothiazide SodiumInjection, powder, lyophilized, for solution500 mg/18mLIntravenousAmerican Regent, Inc.2015-04-01Not applicableUs
Chlorothiazide SodiumInjection, powder, lyophilized, for solution500 mg/18mLIntravenousSagent Pharmaceuticals2015-10-12Not applicableUs
Chlorothiazide SodiumInjection, powder, lyophilized, for solution500 mg/18mLIntravenousSun Pharma Global FZE2011-08-05Not applicableUs
Chlorothiazide SodiumInjection, powder, lyophilized, for solution500 mg/18mLIntravenousMylan Institutional LLC2014-08-08Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
Supres 150 TabMerck Frosst Canada & Cie, Merck Frosst Canada & Co.
Supres 250 TabMerck Frosst Canada & Cie, Merck Frosst Canada & Co.
Salts
Name/CASStructureProperties
Chlorothiazide Sodium
7085-44-1
Thumb
  • InChI Key: CPIWHAFLBZQYLQ-UHFFFAOYSA-N
  • Monoisotopic Mass: 316.93077
  • Average Mass: 317.69
DBSALT000926
Categories
UNII77W477J15H
CAS number58-94-6
WeightAverage: 295.723
Monoisotopic: 294.948824782
Chemical FormulaC7H6ClN3O4S2
InChI KeyJBMKAUGHUNFTOL-UHFFFAOYSA-N
InChI
InChI=1S/C7H6ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-3H,(H,10,11)(H2,9,12,13)
IUPAC Name
6-chloro-1,1-dioxo-4H-1λ⁶,2,4-benzothiadiazine-7-sulfonamide
SMILES
NS(=O)(=O)C1=C(Cl)C=C2NC=NS(=O)(=O)C2=C1
Pharmacology
IndicationChlorothiazide is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. It is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension.
Structured Indications
PharmacodynamicsLike other thiazides, chlorothiazide promotes water loss from the body (diuretics). It inhibits Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue. Chlorothiazide affects the distal renal tubular mechanism of electrolyte reabsorption. At maximal therapeutic dosages, all thiazides are approximately equal in their diuretic efficacy. Chlorothiazide increases excretion of sodium and chloride in approximately equivalent amounts. Natriuresis may be accompanied by some loss of potassium and bicarbonate. After oral doses, 10-15 percent of the dose is excreted unchanged in the urine. Chlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.
Mechanism of actionAs a diuretic, chlorothiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like chlorothiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of chlorothiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle.
TargetKindPharmacological actionActionsOrganismUniProt ID
Solute carrier family 12 member 3Proteinyes
inhibitor
HumanP55017 details
Carbonic anhydrase 1Proteinyes
inhibitor
HumanP00915 details
Carbonic anhydrase 2Proteinyes
inhibitor
HumanP00918 details
Carbonic anhydrase 4Proteinyes
inhibitor
HumanP22748 details
Related Articles
AbsorptionRapidly absorbed following oral administration.
Volume of distributionNot Available
Protein bindingApproximately 40% bound to plasma proteins.
Metabolism

Chlorothiazide is not metabolized but is eliminated rapidly by the kidney.

Route of eliminationChlorothiazide is not metabolized but is eliminated rapidly by the kidney. After oral doses, 10 to 15 percent of the dose is excreted unchanged in the urine. Chlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.
Half life45-120 minutes
ClearanceNot Available
ToxicityOral, rat LD50: > 10 g/kg. Signs of overdose include those caused by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration resulting from excessive diuresis. If digitalis has also been administered hypokalemia may accentuate cardiac arrhythmias.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Chlorothiazide Action PathwayDrug actionSMP00078
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the hypokalemic activities of Chlorothiazide.Investigational
19-norandrostenedione19-norandrostenedione may increase the hypokalemic activities of Chlorothiazide.Experimental, Illicit
4-Androstenedione4-Androstenedione may increase the hypokalemic activities of Chlorothiazide.Experimental, Illicit
5-androstenedione5-androstenedione may increase the hypokalemic activities of Chlorothiazide.Experimental, Illicit
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Chlorothiazide.Experimental
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Chlorothiazide.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Acebutolol.Approved
AceclofenacThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Aceclofenac.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Acetazolamide.Approved, Vet Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Chlorothiazide.Withdrawn
AcetovanilloneThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Acetovanillone.Investigational
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Acetyldigitoxin.Approved
Acetylsalicylic acidThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AclidiniumThe serum concentration of Chlorothiazide can be increased when it is combined with Aclidinium.Approved
AdapaleneThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Adapalene.Approved
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Chlorothiazide.Experimental
AlclometasoneAlclometasone may increase the hypokalemic activities of Chlorothiazide.Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Chlorothiazide.Approved
AldosteroneAldosterone may increase the hypokalemic activities of Chlorothiazide.Experimental
AlfacalcidolChlorothiazide may increase the hypercalcemic activities of Alfacalcidol.Approved, Nutraceutical
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Chlorothiazide.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Chlorothiazide.Approved, Investigational
AliskirenThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Aliskiren.Approved, Investigational
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Chlorothiazide.Approved
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Chlorothiazide.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Chlorothiazide.Experimental, Illicit
AlprenololAlprenolol may increase the hypotensive activities of Chlorothiazide.Approved, Withdrawn
AmbrisentanChlorothiazide may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmcinonideAmcinonide may increase the hypokalemic activities of Chlorothiazide.Approved
AmifostineChlorothiazide may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Chlorothiazide.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Chlorothiazide.Approved
AmobarbitalAmobarbital may increase the orthostatic hypotensive activities of Chlorothiazide.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Amyl Nitrite.Approved
AnecortaveAnecortave may increase the hypokalemic activities of Chlorothiazide.Investigational
AnisodamineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Anisodamine.Investigational
Anisotropine MethylbromideThe serum concentration of Chlorothiazide can be increased when it is combined with Anisotropine Methylbromide.Approved
AntipyrineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Antipyrine.Approved
AnvirzelThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Anvirzel.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Apraclonidine.Approved
ApremilastThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Apremilast.Approved, Investigational
ArbutamineArbutamine may increase the hypokalemic activities of Chlorothiazide.Approved
ArformoterolArformoterol may increase the hypokalemic activities of Chlorothiazide.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Chlorothiazide.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Arsenic trioxide.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Chlorothiazide.Approved
Atracurium besylateThe serum concentration of Chlorothiazide can be increased when it is combined with Atracurium besylate.Approved
AtropineThe serum concentration of Chlorothiazide can be increased when it is combined with Atropine.Approved, Vet Approved
AzapropazoneThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Azilsartan medoxomil.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Chlorothiazide.Investigational
BalsalazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Balsalazide.Approved, Investigational
BambuterolBambuterol may increase the hypokalemic activities of Chlorothiazide.Approved
BarbexacloneBarbexaclone may increase the orthostatic hypotensive activities of Chlorothiazide.Experimental
BarbitalBarbital may increase the orthostatic hypotensive activities of Chlorothiazide.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Barnidipine.Approved
BeclomethasoneBeclomethasone may increase the hypokalemic activities of Chlorothiazide.Investigational
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Chlorothiazide.Approved, Investigational
BenactyzineThe serum concentration of Chlorothiazide can be increased when it is combined with Benactyzine.Withdrawn
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Chlorothiazide.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Chlorothiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Chlorothiazide.Withdrawn
BenoxaprofenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzatropineThe serum concentration of Chlorothiazide can be increased when it is combined with Benzatropine.Approved
BepridilChlorothiazide may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetamethasoneBetamethasone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Chlorothiazide.Approved
BethanidineBethanidine may increase the hypotensive activities of Chlorothiazide.Approved
Betulinic AcidThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Betulinic Acid.Investigational
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Chlorothiazide.Experimental, Illicit, Withdrawn
BimatoprostChlorothiazide may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BiperidenThe serum concentration of Chlorothiazide can be increased when it is combined with Biperiden.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Chlorothiazide.Approved
BortezomibThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Bortezomib.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Chlorothiazide.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Chlorothiazide.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Chlorothiazide.Approved
BromfenacThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Bromocriptine.Approved, Investigational
BucillamineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Bucillamine.Investigational
BudesonideBudesonide may increase the hypokalemic activities of Chlorothiazide.Approved
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Chlorothiazide.Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Bupivacaine.Approved, Investigational
BupranololChlorothiazide may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Chlorothiazide.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Chlorothiazide.Approved, Illicit, Vet Approved
CalcidiolChlorothiazide may increase the hypercalcemic activities of Calcidiol.Approved, Nutraceutical
CalcipotriolChlorothiazide may increase the hypercalcemic activities of Calcipotriol.Approved
CalcitriolChlorothiazide may increase the hypercalcemic activities of Calcitriol.Approved, Nutraceutical
CalciumChlorothiazide may decrease the excretion rate of Calcium which could result in a higher serum level.Nutraceutical
Calcium AcetateChlorothiazide may decrease the excretion rate of Calcium Acetate which could result in a higher serum level.Approved
Calcium carbonateChlorothiazide may decrease the excretion rate of Calcium carbonate which could result in a higher serum level.Approved
Calcium ChlorideChlorothiazide may decrease the excretion rate of Calcium Chloride which could result in a higher serum level.Approved
Calcium citrateChlorothiazide may decrease the excretion rate of Calcium citrate which could result in a higher serum level.Approved
Calcium glubionateChlorothiazide may decrease the excretion rate of Calcium glubionate which could result in a higher serum level.Approved
Calcium GluceptateChlorothiazide may decrease the excretion rate of Calcium Gluceptate which could result in a higher serum level.Approved
Calcium gluconateChlorothiazide may decrease the excretion rate of Calcium gluconate which could result in a higher serum level.Approved, Vet Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Canagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Chlorothiazide.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Chlorothiazide.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Carbetocin.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Chlorothiazide.Illicit, Vet Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Chlorothiazide.Withdrawn
CarprofenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Chlorothiazide.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Carvedilol.Approved, Investigational
CastanospermineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypokalemic activities of Chlorothiazide.Approved, Investigational
ChloroquineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Chloroquine.Approved, Vet Approved
ChlorphenoxamineThe serum concentration of Chlorothiazide can be increased when it is combined with Chlorphenoxamine.Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Chlorothiazide.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Chlorothiazide.Approved
CholecalciferolChlorothiazide may increase the hypercalcemic activities of Cholecalciferol.Approved, Nutraceutical
CholestyramineCholestyramine can cause a decrease in the absorption of Chlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CiclesonideCiclesonide may increase the hypokalemic activities of Chlorothiazide.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Chlorothiazide.Experimental
CilazaprilThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Cilnidipine.Approved
CitalopramCitalopram may increase the hyponatremic activities of Chlorothiazide.Approved
ClenbuterolClenbuterol may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Clevidipine.Approved
ClobetasolClobetasol may increase the hypokalemic activities of Chlorothiazide.Investigational
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Chlorothiazide.Approved
ClocortoloneClocortolone may increase the hypokalemic activities of Chlorothiazide.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Chlorothiazide.Approved
ClonixinThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Clonixin.Approved
ClozapineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Clozapine.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Chlorothiazide.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Chlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Chlorothiazide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Conivaptan.Approved, Investigational
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Chlorothiazide.Approved
CryptenamineCryptenamine may increase the hypotensive activities of Chlorothiazide.Approved
CurcuminThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Curcumin.Investigational
CyclopentolateThe serum concentration of Chlorothiazide can be increased when it is combined with Cyclopentolate.Approved
CyclophosphamideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Cyclophosphamide.Approved, Investigational
CyclothiazideCyclothiazide may increase the hypotensive activities of Chlorothiazide.Approved
D-LimoneneThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with D-Limonene.Investigational
DapagliflozinThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Dapagliflozin.Approved
DapoxetineDapoxetine may increase the hyponatremic activities of Chlorothiazide.Investigational
DarifenacinThe serum concentration of Chlorothiazide can be increased when it is combined with Darifenacin.Approved, Investigational
DebrisoquinChlorothiazide may increase the hypotensive activities of Debrisoquin.Approved
dehydroepiandrosterone sulfatedehydroepiandrosterone sulfate may increase the hypokalemic activities of Chlorothiazide.Investigational
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Chlorothiazide.Investigational
DeserpidineChlorothiazide may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Desflurane.Approved
DeslanosideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Deslanoside.Approved
DesloratadineThe serum concentration of Chlorothiazide can be increased when it is combined with Desloratadine.Approved, Investigational
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Chlorothiazide.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Chlorothiazide.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the hypokalemic activities of Chlorothiazide.Experimental, Vet Approved
DesvenlafaxineDesvenlafaxine may increase the hyponatremic activities of Chlorothiazide.Approved
DexamethasoneDexamethasone may increase the hypokalemic activities of Chlorothiazide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Chlorothiazide.Vet Approved
DexetimideThe serum concentration of Chlorothiazide can be increased when it is combined with Dexetimide.Withdrawn
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Chlorothiazide.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Chlorothiazide.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Chlorothiazide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Chlorothiazide.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Chlorothiazide.Approved
DiazoxideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Diazoxide.Approved
DiclofenacThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Diclofenamide.Approved
DicyclomineThe serum concentration of Chlorothiazide can be increased when it is combined with Dicyclomine.Approved
DiflorasoneDiflorasone may increase the hypokalemic activities of Chlorothiazide.Approved
DiflunisalThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Diflunisal.Approved
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Chlorothiazide.Approved
DifluprednateDifluprednate may increase the hypokalemic activities of Chlorothiazide.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Digitoxin.Approved
DigoxinThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Digoxin.Approved
DihydralazineChlorothiazide may increase the hypotensive activities of Dihydralazine.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chlorothiazide.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Chlorothiazide.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Chlorothiazide.Experimental, Illicit
DihydrotachysterolChlorothiazide may increase the hypercalcemic activities of Dihydrotachysterol.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Chlorothiazide.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Dinutuximab.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chlorothiazide.Approved, Illicit
DipivefrinDipivefrin may increase the hypokalemic activities of Chlorothiazide.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Dipyridamole.Approved
DobutamineDobutamine may increase the hypokalemic activities of Chlorothiazide.Approved
DofetilideChlorothiazide may increase the QTc-prolonging activities of Dofetilide.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Chlorothiazide.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Chlorothiazide.Approved
DoxercalciferolChlorothiazide may increase the hypercalcemic activities of Doxercalciferol.Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Chlorothiazide.Investigational
DroxicamThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Droxicam.Approved
DroxidopaDroxidopa may increase the hypokalemic activities of Chlorothiazide.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Chlorothiazide.Approved
DuloxetineChlorothiazide may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Duvelisib.Investigational
E6201The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with E6201.Investigational
EbselenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ebselen.Investigational
EfonidipineChlorothiazide may increase the hypotensive activities of Efonidipine.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Chlorothiazide.Approved, Vet Approved
EnalaprilatChlorothiazide may increase the hypotensive activities of Enalaprilat.Approved
EphedraEphedra may increase the hypokalemic activities of Chlorothiazide.Approved, Nutraceutical, Withdrawn
EpinephrineEpinephrine may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
EpirizoleThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Epirizole.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Chlorothiazide.Approved
EpoprostenolChlorothiazide may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Chlorothiazide.Approved
EquileninEquilenin may increase the hypokalemic activities of Chlorothiazide.Experimental
EquilinEquilin may increase the hypokalemic activities of Chlorothiazide.Approved
ErgocalciferolChlorothiazide may increase the hypercalcemic activities of Ergocalciferol.Approved, Nutraceutical
EscitalopramEscitalopram may increase the hyponatremic activities of Chlorothiazide.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Chlorothiazide.Approved
EstroneEstrone may increase the hypokalemic activities of Chlorothiazide.Approved
Estrone sulfateEstrone sulfate may increase the hypokalemic activities of Chlorothiazide.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Etacrynic acid.Approved
EtanerceptThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Etanercept.Approved, Investigational
EthanolEthanol may increase the orthostatic hypotensive activities of Chlorothiazide.Approved
EthopropazineThe serum concentration of Chlorothiazide can be increased when it is combined with Ethopropazine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Chlorothiazide.Approved, Illicit
EtodolacThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Etofenamate.Approved
EtoperidoneEtoperidone may increase the hyponatremic activities of Chlorothiazide.Approved
EtoricoxibThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Etoricoxib.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Chlorothiazide.Illicit, Vet Approved
Evening primrose oilThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Evening primrose oil.Approved
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Chlorothiazide.Approved, Investigational
exisulindThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with exisulind.Investigational
FelodipineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Felodipine.Approved, Investigational
FenbufenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Fenbufen.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Chlorothiazide.Approved
FenoprofenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Fenoprofen.Approved
FenoterolFenoterol may increase the hypokalemic activities of Chlorothiazide.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chlorothiazide.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Chlorothiazide can be increased when it is combined with Fesoterodine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Fimasartan.Approved
FloctafenineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Floctafenine.Approved, Withdrawn
fluasteronefluasterone may increase the hypokalemic activities of Chlorothiazide.Investigational
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Chlorothiazide.Approved
FlumethasoneFlumethasone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
FlunisolideFlunisolide may increase the hypokalemic activities of Chlorothiazide.Approved, Investigational
FlunixinThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Flunixin.Vet Approved
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Chlorothiazide.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hypokalemic activities of Chlorothiazide.Approved, Investigational
FluocortoloneFluocortolone may increase the hypokalemic activities of Chlorothiazide.Approved, Withdrawn
FluorometholoneFluorometholone may increase the hypokalemic activities of Chlorothiazide.Approved
FluoxetineFluoxetine may increase the hyponatremic activities of Chlorothiazide.Approved, Vet Approved
FluprednideneFluprednidene may increase the hypokalemic activities of Chlorothiazide.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Chlorothiazide.Approved
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Chlorothiazide.Approved
FlurbiprofenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Flurbiprofen.Approved, Investigational
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Chlorothiazide.Approved
Fluticasone PropionateFluticasone Propionate may increase the hypokalemic activities of Chlorothiazide.Approved
FluvoxamineFluvoxamine may increase the hyponatremic activities of Chlorothiazide.Approved, Investigational
FormestaneFormestane may increase the hypokalemic activities of Chlorothiazide.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the hypokalemic activities of Chlorothiazide.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Chlorothiazide.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Chlorothiazide.Approved, Vet Approved
Gallamine TriethiodideThe serum concentration of Chlorothiazide can be increased when it is combined with Gallamine Triethiodide.Approved
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Chlorothiazide.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Chlorothiazide.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Chlorothiazide.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Chlorothiazide.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Chlorothiazide.Approved
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Chlorothiazide.Approved
GlycopyrroniumThe serum concentration of Chlorothiazide can be increased when it is combined with Glycopyrronium.Approved, Investigational, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Chlorothiazide.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Chlorothiazide.Approved
GuanethidineChlorothiazide may increase the hypotensive activities of Guanethidine.Approved
GuanfacineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Guanfacine.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Chlorothiazide.Investigational
HalothaneThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Halothane.Approved, Vet Approved
HE3286HE3286 may increase the hypokalemic activities of Chlorothiazide.Investigational
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Chlorothiazide.Approved, Illicit
HexamethoniumThe serum concentration of Chlorothiazide can be increased when it is combined with Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the orthostatic hypotensive activities of Chlorothiazide.Approved
HigenamineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Higenamine.Investigational
HMPL-004The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with HMPL-004.Investigational
HomatropineThe serum concentration of Chlorothiazide can be increased when it is combined with Homatropine.Approved
HydracarbazineHydracarbazine may increase the hypotensive activities of Chlorothiazide.Approved
HydralazineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Chlorothiazide.Approved, Illicit
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Chlorothiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Chlorothiazide.Approved, Illicit
HyoscyamineThe serum concentration of Chlorothiazide can be increased when it is combined with Hyoscyamine.Approved
IbuprofenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Icatibant.Approved
IloprostIloprost may increase the hypotensive activities of Chlorothiazide.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Imipramine.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Chlorothiazide.Approved
IndalpineIndalpine may increase the hyponatremic activities of Chlorothiazide.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Chlorothiazide.Approved
IndenololChlorothiazide may increase the hypotensive activities of Indenolol.Withdrawn
IndomethacinThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Indoprofen.Withdrawn
IndoraminChlorothiazide may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Chlorothiazide.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Chlorothiazide.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Chlorothiazide.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Chlorothiazide.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Chlorothiazide.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Chlorothiazide.Approved
Ipratropium bromideThe serum concentration of Chlorothiazide can be increased when it is combined with Ipratropium bromide.Approved
IproclozideIproclozide may increase the hypotensive activities of Chlorothiazide.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Chlorothiazide.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Chlorothiazide.Approved
IsoetarineIsoetarine may increase the hypokalemic activities of Chlorothiazide.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Isoflurane.Approved, Vet Approved
IsoprenalineIsoprenaline may increase the hypokalemic activities of Chlorothiazide.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Isosorbide Mononitrate.Approved
IsoxicamThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Chlorothiazide.Approved
IstaroximeIstaroxime may increase the hypokalemic activities of Chlorothiazide.Investigational
IvabradineChlorothiazide may increase the arrhythmogenic activities of Ivabradine.Approved
KebuzoneThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Kebuzone.Experimental
KetanserinChlorothiazide may increase the hypotensive activities of Ketanserin.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Chlorothiazide.Approved
KetoprofenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Chlorothiazide.Approved
LacidipineChlorothiazide may increase the hypotensive activities of Lacidipine.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Chlorothiazide.Approved, Investigational
LeflunomideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Leflunomide.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Chlorothiazide.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Levobupivacaine.Approved
LevodopaChlorothiazide may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Chlorothiazide.Approved
LevomilnacipranLevomilnacipran may increase the hyponatremic activities of Chlorothiazide.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Chlorothiazide.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Levosimendan.Approved, Investigational
LicoriceLicorice may increase the hypokalemic activities of Chlorothiazide.Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Chlorothiazide.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Chlorothiazide.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Chlorothiazide.Approved, Investigational
LisofyllineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Lisofylline.Investigational
LithiumChlorothiazide may decrease the excretion rate of Lithium which could result in a higher serum level.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Chlorothiazide.Illicit
LofexidineChlorothiazide may increase the hypotensive activities of Lofexidine.Approved, Investigational
LornoxicamThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Lornoxicam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Chlorothiazide.Approved
LoxoprofenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Loxoprofen.Approved
LumiracoxibThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Lumiracoxib.Approved, Investigational
MacitentanChlorothiazide may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Magnesium salicylate.Approved
ManidipineChlorothiazide may increase the hypotensive activities of Manidipine.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Chlorothiazide.Approved, Investigational
MasoprocolThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Masoprocol.Approved
ME-609ME-609 may increase the hypokalemic activities of Chlorothiazide.Investigational
MebanazineMebanazine may increase the hypotensive activities of Chlorothiazide.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Mecamylamine.Approved
Meclofenamic acidThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
MedrysoneMedrysone may increase the hypokalemic activities of Chlorothiazide.Approved
Mefenamic acidThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mefenamic acid.Approved
MelengestrolMelengestrol may increase the hypokalemic activities of Chlorothiazide.Vet Approved
MeloxicamThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MesalazineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Metamizole.Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Chlorothiazide.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Chlorothiazide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Chlorothiazide.Approved, Illicit
MethanthelineThe serum concentration of Chlorothiazide can be increased when it is combined with Methantheline.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Chlorothiazide.Approved
MethohexitalMethohexital may increase the orthostatic hypotensive activities of Chlorothiazide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Chlorothiazide.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Chlorothiazide.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Chlorothiazide.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the orthostatic hypotensive activities of Chlorothiazide.Approved
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
MetipranololThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Metipranolol.Approved
MetixeneThe serum concentration of Chlorothiazide can be increased when it is combined with Metixene.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Chlorothiazide.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Chlorothiazide.Approved, Investigational
MetyrosineChlorothiazide may increase the hypotensive activities of Metyrosine.Approved
MibefradilChlorothiazide may increase the hypotensive activities of Mibefradil.Withdrawn
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Chlorothiazide.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Chlorothiazide.Approved
MilnacipranMilnacipran may increase the hyponatremic activities of Chlorothiazide.Approved
MinaprineMinaprine may increase the hypotensive activities of Chlorothiazide.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Chlorothiazide.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Chlorothiazide.Approved, Investigational
MizoribineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mizoribine.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Chlorothiazide.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Chlorothiazide.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Chlorothiazide.Approved
MometasoneMometasone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Chlorothiazide.Approved, Investigational
MoxonidineChlorothiazide may increase the hypotensive activities of Moxonidine.Approved
Mycophenolate mofetilThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mycophenolic acid.Approved
N-butylscopolammonium bromideThe serum concentration of Chlorothiazide can be increased when it is combined with N-butylscopolammonium bromide.Vet Approved
NabiloneThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Nabilone.Approved, Investigational
NabumetoneThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Nadolol.Approved
NafamostatThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nafamostat.Investigational
NaftifineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Naftifine.Approved
NaftopidilChlorothiazide may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Chlorothiazide.Approved
NaproxenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Naproxen.Approved, Vet Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Chlorothiazide.Approved, Investigational
NCX 1022NCX 1022 may increase the hypokalemic activities of Chlorothiazide.Investigational
NCX 4016The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with NCX 4016.Investigational
NebivololThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the hyponatremic activities of Chlorothiazide.Approved, Withdrawn
NepafenacThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nepafenac.Approved
NesiritideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Nesiritide.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Chlorothiazide.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Chlorothiazide.Approved
NicorandilNicorandil may increase the hypotensive activities of Chlorothiazide.Approved
NifedipineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Nifedipine.Approved
Niflumic AcidThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Niflumic Acid.Approved
NiguldipineChlorothiazide may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineChlorothiazide may increase the hypotensive activities of Nilvadipine.Approved
NimesulideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Chlorothiazide.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Chlorothiazide.Approved
NitrendipineChlorothiazide may increase the hypotensive activities of Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Nitric Oxide.Approved
NitroaspirinThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Chlorothiazide.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Chlorothiazide.Approved
NorepinephrineNorepinephrine may increase the hypokalemic activities of Chlorothiazide.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Chlorothiazide.Approved, Illicit
NVA237The serum concentration of Chlorothiazide can be increased when it is combined with NVA237.Investigational
ObinutuzumabChlorothiazide may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Chlorothiazide.Withdrawn
Oleoyl estroneOleoyl estrone may increase the hypokalemic activities of Chlorothiazide.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Chlorothiazide.Approved, Investigational
OlodaterolOlodaterol may increase the hypokalemic activities of Chlorothiazide.Approved
OlopatadineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Olsalazine.Approved
OmapatrilatChlorothiazide may increase the hypotensive activities of Omapatrilat.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Chlorothiazide.Approved, Illicit
OrciprenalineOrciprenaline may increase the hypokalemic activities of Chlorothiazide.Approved
OrgoteinThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Orgotein.Vet Approved
OrphenadrineThe serum concentration of Chlorothiazide can be increased when it is combined with Orphenadrine.Approved
OuabainThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Ouabain.Approved
OxaprozinThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Oxaprozin.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Oxcarbazepine.Approved
OxprenololChlorothiazide may increase the hypotensive activities of Oxprenolol.Approved
OxybutyninThe serum concentration of Chlorothiazide can be increased when it is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chlorothiazide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Chlorothiazide.Approved, Investigational, Vet Approved
OxyphenbutazoneThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Oxyphenbutazone.Withdrawn
OxyphenoniumThe serum concentration of Chlorothiazide can be increased when it is combined with Oxyphenonium.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Paclitaxel.Approved, Vet Approved
PancuroniumThe serum concentration of Chlorothiazide can be increased when it is combined with Pancuronium.Approved
PapaverineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Papaverine.Approved
ParamethasoneParamethasone may increase the hypokalemic activities of Chlorothiazide.Approved
ParecoxibThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Chlorothiazide.Approved
ParicalcitolChlorothiazide may increase the hypercalcemic activities of Paricalcitol.Approved, Investigational
ParoxetineParoxetine may increase the hyponatremic activities of Chlorothiazide.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chlorothiazide.Approved, Vet Approved
PentobarbitalPentobarbital may increase the orthostatic hypotensive activities of Chlorothiazide.Approved, Vet Approved
PentoliniumThe serum concentration of Chlorothiazide can be increased when it is combined with Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Chlorothiazide.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Chlorothiazide.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Chlorothiazide.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Chlorothiazide.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Chlorothiazide.Approved, Withdrawn
PheniprazinePheniprazine may increase the hypotensive activities of Chlorothiazide.Withdrawn
PhenobarbitalPhenobarbital may increase the orthostatic hypotensive activities of Chlorothiazide.Approved
PhenoxybenzamineChlorothiazide may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Chlorothiazide.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Chlorothiazide.Approved
PhenylbutazoneThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved, Withdrawn
PimecrolimusThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PinacidilChlorothiazide may increase the hypotensive activities of Pinacidil.Withdrawn
PindololThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Pindolol.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Chlorothiazide.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Pipamperone.Approved
PipecuroniumThe serum concentration of Chlorothiazide can be increased when it is combined with Pipecuronium.Approved
PirbuterolPirbuterol may increase the hypokalemic activities of Chlorothiazide.Approved
PirenzepineThe serum concentration of Chlorothiazide can be increased when it is combined with Pirenzepine.Approved
PirfenidoneThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Pirfenidone.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Chlorothiazide.Investigational
PirlindolePirlindole may increase the hypotensive activities of Chlorothiazide.Approved
PiroxicamThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Piroxicam.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Chlorothiazide.Withdrawn
PolythiazideChlorothiazide may increase the hypotensive activities of Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Pramipexole.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Chlorothiazide.Approved, Investigational
PrasteronePrasterone may increase the hypokalemic activities of Chlorothiazide.Approved, Nutraceutical
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Chlorothiazide.Approved
PrednicarbatePrednicarbate may increase the hypokalemic activities of Chlorothiazide.Approved
PrednisolonePrednisolone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
PrednisonePrednisone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
PregnenolonePregnenolone may increase the hypokalemic activities of Chlorothiazide.Experimental
PrimidonePrimidone may increase the orthostatic hypotensive activities of Chlorothiazide.Approved, Vet Approved
ProcaterolProcaterol may increase the hypokalemic activities of Chlorothiazide.Approved
ProcyclidineThe serum concentration of Chlorothiazide can be increased when it is combined with Procyclidine.Approved
PropacetamolThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Propacetamol.Approved
PropanthelineThe serum concentration of Chlorothiazide can be increased when it is combined with Propantheline.Approved
PropiverineThe serum concentration of Chlorothiazide can be increased when it is combined with Propiverine.Investigational
PropofolThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Chlorothiazide.Approved, Investigational
PTC299The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with PTC299.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Chlorothiazide can be increased when it is combined with Quinidine.Approved
QuinineQuinine may increase the hypotensive activities of Chlorothiazide.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Chlorothiazide.Approved
RasagilineRasagiline may increase the hypotensive activities of Chlorothiazide.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chlorothiazide.Approved
RemikirenRemikiren may increase the hypotensive activities of Chlorothiazide.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Chlorothiazide.Approved, Investigational
RescinnamineChlorothiazide may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Chlorothiazide.Approved
ResveratrolThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Resveratrol.Experimental, Investigational
RilmenidineChlorothiazide may increase the hypotensive activities of Rilmenidine.Investigational
RimexoloneRimexolone may increase the hypokalemic activities of Chlorothiazide.Approved
RiociguatThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Riociguat.Approved
RisperidoneChlorothiazide may increase the hypotensive activities of Risperidone.Approved, Investigational
RitodrineRitodrine may increase the hypokalemic activities of Chlorothiazide.Approved
RituximabChlorothiazide may increase the hypotensive activities of Rituximab.Approved
RofecoxibThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Rofecoxib.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Ropivacaine.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Chlorothiazide.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypotensive activities of Chlorothiazide.Withdrawn
SalbutamolSalbutamol may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
SalicylamideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Salicylic acid.Approved, Vet Approved
SalmeterolSalmeterol may increase the hypokalemic activities of Chlorothiazide.Approved
SalsalateThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Salsalate.Approved
SaprisartanChlorothiazide may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Chlorothiazide.Approved
ScopolamineThe serum concentration of Chlorothiazide can be increased when it is combined with Scopolamine.Approved
Scopolamine butylbromideThe serum concentration of Chlorothiazide can be increased when it is combined with Scopolamine butylbromide.Approved
SecobarbitalSecobarbital may increase the orthostatic hypotensive activities of Chlorothiazide.Approved, Vet Approved
SelegilineSelegiline may increase the hypotensive activities of Chlorothiazide.Approved, Investigational, Vet Approved
SelexipagChlorothiazide may increase the hypotensive activities of Selexipag.Approved
SeratrodastThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Seratrodast.Approved, Investigational
SertralineSertraline may increase the hyponatremic activities of Chlorothiazide.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Sevoflurane.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Chlorothiazide.Approved, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Chlorothiazide.Approved, Investigational
SitaxentanChlorothiazide may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Sodium Nitrite.Approved
SolifenacinThe serum concentration of Chlorothiazide can be increased when it is combined with Solifenacin.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Chlorothiazide.Approved
SpiraprilChlorothiazide may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Chlorothiazide.Approved
SRT501The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with SRT501.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorothiazide.Approved, Investigational
SulfasalazineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Sulindac.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Chlorothiazide.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Sulpiride.Approved
SuprofenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Suprofen.Approved, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Chlorothiazide.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Tamsulosin.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Chlorothiazide.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Telmisartan.Approved, Investigational
TemocaprilChlorothiazide may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenoxicamThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Terazosin.Approved
TerbutalineTerbutaline may increase the hypokalemic activities of Chlorothiazide.Approved
TeriflunomideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Teriflunomide.Approved
TerlipressinChlorothiazide may increase the hypotensive activities of Terlipressin.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the orthostatic hypotensive activities of Chlorothiazide.Approved, Vet Approved
ThiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Chlorothiazide.Investigational
ThiopentalThiopental may increase the orthostatic hypotensive activities of Chlorothiazide.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Thioridazine.Approved
Tiaprofenic acidThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tiaprofenic acid.Approved
TiboloneChlorothiazide may increase the hypotensive activities of Tibolone.Approved
TicrynafenChlorothiazide may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Chlorothiazide.Approved
TinoridineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tinoridine.Investigational
TiotropiumThe serum concentration of Chlorothiazide can be increased when it is combined with Tiotropium.Approved
TixocortolTixocortol may increase the hypokalemic activities of Chlorothiazide.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Chlorothiazide.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Chlorothiazide.Approved
TolazolineTolazoline may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Chlorothiazide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tolfenamic Acid.Approved
TolmetinThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tolmetin.Approved
ToloxatoneToloxatone may increase the hypotensive activities of Chlorothiazide.Approved
TolterodineThe serum concentration of Chlorothiazide can be increased when it is combined with Tolterodine.Approved, Investigational
TopiramateChlorothiazide may increase the hypokalemic activities of Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Chlorothiazide.Approved
ToremifeneChlorothiazide may increase the hypercalcemic activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Chlorothiazide.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Chlorothiazide.Approved
TranilastThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Chlorothiazide.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Chlorothiazide.Approved
TravoprostTravoprost may increase the hypotensive activities of Chlorothiazide.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Chlorothiazide.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Chlorothiazide.Approved
TrichlormethiazideChlorothiazide may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrihexyphenidylThe serum concentration of Chlorothiazide can be increased when it is combined with Trihexyphenidyl.Approved
TrimazosinChlorothiazide may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanThe serum concentration of Chlorothiazide can be increased when it is combined with Trimethaphan.Approved
Trisalicylate-cholineThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Trisalicylate-choline.Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Chlorothiazide.Withdrawn
TropicamideThe serum concentration of Chlorothiazide can be increased when it is combined with Tropicamide.Approved
TrospiumThe serum concentration of Chlorothiazide can be increased when it is combined with Trospium.Approved
TubocurarineThe serum concentration of Chlorothiazide can be increased when it is combined with Tubocurarine.Approved
UdenafilUdenafil may increase the antihypertensive activities of Chlorothiazide.Approved, Investigational
UmeclidiniumThe serum concentration of Chlorothiazide can be increased when it is combined with Umeclidinium.Approved
UnoprostoneChlorothiazide may increase the hypotensive activities of Unoprostone.Approved
ValdecoxibThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Valdecoxib.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Chlorothiazide.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Chlorothiazide.Approved
VecuroniumThe serum concentration of Chlorothiazide can be increased when it is combined with Vecuronium.Approved
VenlafaxineVenlafaxine may increase the hyponatremic activities of Chlorothiazide.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Chlorothiazide.Approved
VilanterolVilanterol may increase the hypokalemic activities of Chlorothiazide.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Chlorothiazide.Approved, Investigational
VinpocetineChlorothiazide may increase the hypotensive activities of Vinpocetine.Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Chlorothiazide.Approved, Investigational
XylometazolineChlorothiazide may increase the hypotensive activities of Xylometazoline.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Chlorothiazide.Approved, Vet Approved
ZaltoprofenThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Zaltoprofen.Approved
ZileutonThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZimelidineZimelidine may increase the hyponatremic activities of Chlorothiazide.Withdrawn
ZomepiracThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Zomepirac.Withdrawn
Food InteractionsNot Available
References
Synthesis Reference

Eugene S. Barabas, “Water soluble complex of a poly (vinyl lactam) and chlorothiazide and process for producing same.” U.S. Patent US4713238, issued December, 1985.

US4713238
General ReferencesNot Available
External Links
ATC CodesC03AB04C03AA04C03AH01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (72.7 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9119
Blood Brain Barrier-0.9506
Caco-2 permeable-0.7368
P-glycoprotein substrateNon-substrate0.706
P-glycoprotein inhibitor INon-inhibitor0.8482
P-glycoprotein inhibitor IINon-inhibitor0.8381
Renal organic cation transporterNon-inhibitor0.8177
CYP450 2C9 substrateNon-substrate0.755
CYP450 2D6 substrateNon-substrate0.8379
CYP450 3A4 substrateNon-substrate0.6308
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9382
CYP450 3A4 inhibitorNon-inhibitor0.8901
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8658
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.7792
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.5023 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9654
hERG inhibition (predictor II)Non-inhibitor0.9352
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Salix pharmaceuticals inc
  • Abc holding corp
  • Lederle laboratories div american cyanamid co
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Watson laboratories inc
  • West ward pharmaceutical corp
  • Lundbeck inc
  • App pharmaceuticals llc
Packagers
Dosage forms
FormRouteStrength
TabletOral250 mg/1
TabletOral500 mg/1
InjectionIntravenous500 mg/1
Injection, powder, lyophilized, for solutionIntravenous500 mg/18mL
SuspensionOral250 mg/5mL
InjectionIntravenous.5 mg/18mL
TabletOral
Prices
Unit descriptionCostUnit
Diuril sodium 500 mg vial519.62USD vial
Chlorothiazide sod 500 mg vial357.24USD vial
Microzide 12.5 mg capsule0.95USD capsule
Aldoclor 250-250 mg tablet0.67USD tablet
Chlorothiazide 500 mg tablet0.36USD tablet
Chlorothiazide 250 mg tablet0.28USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point342.5-343Novello, F.C.; US. Patent 2,809,194; October 8,1957; assigned to Merck & Co.,Inc. Hinkley, D.F.; US. Patent 2,937,169; May 17,1960; assigned to Merck & Co., Inc.
water solubility266 mg/L (at 30 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP-0.24HANSCH,C ET AL. (1995)
logS-3.05ADME Research, USCD
Caco2 permeability-6.72ADME Research, USCD
pKa6.85MERCK INDEX (1996)
Predicted Properties
PropertyValueSource
Water Solubility0.398 mg/mLALOGPS
logP0.41ALOGPS
logP-0.44ChemAxon
logS-2.9ALOGPS
pKa (Strongest Acidic)9.1ChemAxon
pKa (Strongest Basic)1.15ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area118.69 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity62.51 m3·mol-1ChemAxon
Polarizability24.55 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (10.1 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzothiadiazines. These are organic compounds containing a benzene fused to a thiadiazine ring (a six-member ring with two nitrogen atoms and a sulfur atom).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassThiadiazines
Sub ClassBenzothiadiazines
Direct ParentBenzothiadiazines
Alternative Parents
Substituents
  • Benzothiadiazine
  • Benzenesulfonamide
  • Chlorobenzene
  • Benzenoid
  • Aryl halide
  • Aryl chloride
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Azacycle
  • Amidine
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Transporter activity
Specific Function:
Key mediator of sodium and chloride reabsorption in this nephron segment, accounting for a significant fraction of renal sodium reabsorption.
Gene Name:
SLC12A3
Uniprot ID:
P55017
Molecular Weight:
113138.04 Da
References
  1. Thakker RV: Molecular pathology of renal chloride channels in Dent's disease and Bartter's syndrome. Exp Nephrol. 2000 Nov-Dec;8(6):351-60. [PubMed:11014932 ]
  2. Schmidt H, Kabesch M, Schwarz HP, Kiess W: Clinical, biochemical and molecular genetic data in five children with Gitelman's syndrome. Horm Metab Res. 2001 Jun;33(6):354-7. [PubMed:11456284 ]
  3. Wilson FH, Kahle KT, Sabath E, Lalioti MD, Rapson AK, Hoover RS, Hebert SC, Gamba G, Lifton RP: Molecular pathogenesis of inherited hypertension with hyperkalemia: the Na-Cl cotransporter is inhibited by wild-type but not mutant WNK4. Proc Natl Acad Sci U S A. 2003 Jan 21;100(2):680-4. Epub 2003 Jan 6. [PubMed:12515852 ]
  4. Maki N, Komatsuda A, Wakui H, Ohtani H, Kigawa A, Aiba N, Hamai K, Motegi M, Yamaguchi A, Imai H, Sawada K: Four novel mutations in the thiazide-sensitive Na-Cl co-transporter gene in Japanese patients with Gitelman's syndrome. Nephrol Dial Transplant. 2004 Jul;19(7):1761-6. Epub 2004 Apr 6. [PubMed:15069170 ]
  5. Reinalter SC, Jeck N, Peters M, Seyberth HW: Pharmacotyping of hypokalaemic salt-losing tubular disorders. Acta Physiol Scand. 2004 Aug;181(4):513-21. [PubMed:15283765 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name:
CA1
Uniprot ID:
P00915
Molecular Weight:
28870.0 Da
References
  1. Puscas I, Coltau M, Baican M, Domuta G, Hecht A: Vasodilatory effect of diuretics is dependent on inhibition of vascular smooth muscle carbonic anhydrase by a direct mechanism of action. Drugs Exp Clin Res. 1999;25(6):271-9. [PubMed:10713865 ]
  2. Puscas I, Coltau M, Baican M, Pasca R, Domuta G: The inhibitory effect of diuretics on carbonic anhydrases. Res Commun Mol Pathol Pharmacol. 1999;105(3):213-36. [PubMed:10954127 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion into the anterior chamber of the eye. Contributes to intracellular pH regulation in the duodenal upper villous epithelium during proton-coupled peptide absorption. Stimulates the chloride-bicarbonate ex...
Gene Name:
CA2
Uniprot ID:
P00918
Molecular Weight:
29245.895 Da
References
  1. Weiner ID, Verlander JW: Renal and hepatic expression of the ammonium transporter proteins, Rh B Glycoprotein and Rh C Glycoprotein. Acta Physiol Scand. 2003 Dec;179(4):331-8. [PubMed:14656370 ]
  2. Puscas I, Coltau M, Baican M, Pasca R, Domuta G: The inhibitory effect of diuretics on carbonic anhydrases. Res Commun Mol Pathol Pharmacol. 1999;105(3):213-36. [PubMed:10954127 ]
  3. Verlander JW, Miller RT, Frank AE, Royaux IE, Kim YH, Weiner ID: Localization of the ammonium transporter proteins RhBG and RhCG in mouse kidney. Am J Physiol Renal Physiol. 2003 Feb;284(2):F323-37. Epub 2002 Oct 8. [PubMed:12388412 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. May stimulate the sodium/bicarbonate transporter activity of SLC4A4 that acts in pH homeostasis. It is essential for acid overload removal from the retina and retina epithelium, and acid release in the choriocapillaris in the choroid.
Gene Name:
CA4
Uniprot ID:
P22748
Molecular Weight:
35032.075 Da
References
  1. Puscas I, Coltau M, Baican M, Domuta G, Hecht A: Vasodilatory effect of diuretics is dependent on inhibition of vascular smooth muscle carbonic anhydrase by a direct mechanism of action. Drugs Exp Clin Res. 1999;25(6):271-9. [PubMed:10713865 ]
  2. Puscas I, Coltau M, Baican M, Pasca R, Domuta G: The inhibitory effect of diuretics on carbonic anhydrases. Res Commun Mol Pathol Pharmacol. 1999;105(3):213-36. [PubMed:10954127 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:
SLC22A6
Uniprot ID:
Q4U2R8
Molecular Weight:
61815.78 Da
References
  1. Uwai Y, Saito H, Hashimoto Y, Inui KI: Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1. J Pharmacol Exp Ther. 2000 Oct;295(1):261-5. [PubMed:10991988 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 11:11